S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
Log in

NYSE:CHEChemed Stock Price, Forecast & News

$445.93
+19.74 (+4.63 %)
(As of 04/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$426.31
Now: $445.93
$450.42
50-Day Range
$351.57
MA: $422.27
$507.20
52-Week Range
$313.49
Now: $445.93
$513.75
Volume107,805 shs
Average Volume113,771 shs
Market Capitalization$7.16 billion
P/E Ratio33.53
Dividend Yield0.30%
Beta0.85
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations. Chemed Corporation was founded in 1970 and is headquartered in Cincinnati, Ohio.
Read More
Chemed logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.3Dividend Strength: 5.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.29 out of 5 stars


Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
CUSIP16359R10
Phone513-762-6690

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.94 billion
Cash Flow$18.47 per share
Book Value$45.39 per share

Profitability

Net Income$219.92 million

Miscellaneous

Employees16,641
Market Cap$7.16 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive CHE News and Ratings via Email

Sign-up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter.


Chemed (NYSE:CHE) Frequently Asked Questions

How has Chemed's stock been impacted by COVID-19 (Coronavirus)?

Chemed's stock was trading at $414.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CHE stock has increased by 7.7% and is now trading at $445.93. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Chemed?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chemed.

When is Chemed's next earnings date?

Chemed is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Chemed.

How were Chemed's earnings last quarter?

Chemed Co. (NYSE:CHE) announced its earnings results on Tuesday, February, 18th. The company reported $4.22 EPS for the quarter, beating the Zacks' consensus estimate of $4.09 by $0.13. The company earned $522.30 million during the quarter, compared to analysts' expectations of $524.20 million. Chemed had a return on equity of 35.38% and a net margin of 11.35%. Chemed's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter last year, the business earned $3.35 EPS. View Chemed's earnings history.

How often does Chemed pay dividends? What is the dividend yield for Chemed?

Chemed declared a quarterly dividend on Friday, February 21st. Shareholders of record on Monday, March 2nd will be given a dividend of $0.32 per share on Monday, March 23rd. This represents a $1.28 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Friday, February 28th. View Chemed's dividend history.

What guidance has Chemed issued on next quarter's earnings?

Chemed issued an update on its FY20 earnings guidance on Tuesday, February, 18th. The company provided earnings per share (EPS) guidance of $16.20-16.50 for the period, compared to the Thomson Reuters consensus estimate of $15.63.

What price target have analysts set for CHE?

4 analysts have issued 1-year price targets for Chemed's stock. Their forecasts range from $490.00 to $535.00. On average, they expect Chemed's share price to reach $515.00 in the next year. This suggests a possible upside of 15.5% from the stock's current price. View analysts' price targets for Chemed.

Has Chemed been receiving favorable news coverage?

Headlines about CHE stock have trended very negative on Wednesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chemed earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutChemed.

Are investors shorting Chemed?

Chemed saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 203,600 shares, a decline of 8.3% from the February 27th total of 222,000 shares. Based on an average trading volume of 86,500 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.3% of the shares of the stock are short sold. View Chemed's Current Options Chain.

Who are some of Chemed's key competitors?

What other stocks do shareholders of Chemed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include Home Depot (HD), Altria Group (MO), AT&T (T), AbbVie (ABBV), Chevron (CVX), Walt Disney (DIS), Boeing (BA), CVS Health (CVS), Costco Wholesale (COST) and Cisco Systems (CSCO).

Who are Chemed's key executives?

Chemed's management team includes the following people:
  • Mr. Kevin J. McNamara, CEO, Pres & Director (Age 65)
  • Mr. David P. Williams, Exec. VP & CFO (Age 58)
  • Ms. Naomi C. Dallob, VP, Chief Legal Officer & Sec. (Age 65)
  • Mr. Spencer S. Lee, Exec. VP (Age 63)
  • Mr. Nicholas Michael Westfall, Exec. VP (Age 40)

What is Chemed's stock symbol?

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Who are Chemed's major shareholders?

Chemed's stock is owned by many different institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View institutional ownership trends for Chemed.

Which institutional investors are buying Chemed stock?

CHE stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Chemed stock in the last two years include Donald E Saunders, and George J Walsh III. View insider buying and selling activity for Chemed.

How do I buy shares of Chemed?

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chemed's stock price today?

One share of CHE stock can currently be purchased for approximately $445.93.

How big of a company is Chemed?

Chemed has a market capitalization of $7.16 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 16,641 workers across the globe. View additional information about Chemed.

What is Chemed's official website?

The official website for Chemed is http://www.chemed.com/.

How can I contact Chemed?

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202-4726. The company can be reached via phone at 513-762-6690.

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel